Table 2.

The application of PI3K/Akt/mTOR inhibitors in different cancers

Target	Drug name	Tumor type		ID number and the highest developmental stage		Status
PI3K inhibitors
PI3K pan-inhibitor	Copanlisib	Lymphoma				Marketed
	Buparlisib (NVP-BKM120)	Head and neck cancer		Phase III — NCT04338399		Active
PI3Kα	Alpelisib	Breast cancer				Marketed
	Inavolisib (GDC-0077)	Breast cancer		Phase III — NCT04191499		Active
	Serabelisib (INK-1117)	Solid tumor		Phase II — NCT04073680		Active
	MEN1611 (CH5132799)	Colorectal cancer		Phase II — NCT04495621		Active
	CYH-33 (HHCYH-33)	Solid tumor		Phase I — NCT04586335, NCT04856371		Active
PI3Kβ	AZD8186	Solid tumor		Phase II — NCT04001569		Active
	GSK2636771	Lymphoma, myeloma, solid tumor		Phase II — NCT02465060		Active
PI3Kγ	Eganelisib (IPI-549)	Breast cancer, kidney cancer		Phase II — NCT03961698		Active
PI3Kδ	Idelalisib	Lymphoma, leukemia				Marketed
	Umbralisib	Lymphoma				Marketed
	Parsaclisib (INCB50465)	Myelofibrosis, lymphoma		Phase III — NCT04551066, NCT04551053, NCT04796922, NCT04849715		Active
	Zandelisib (PWT-143)	Lymphoma		Phase III — NCT04745832		Active
	SHC014748 (SH-748)	Lymphoma		Phase II — NCT04470141, NCT04431089		Active
	Linperlisib (YY-20394)	Lymphoma		Phase II — NCT04500561, NCT04705090, NCT04370405, NCT04379167, NCT04948788		Active
	IOA-244	Lymphoma, melanoma, solid tumor		Phase I — NCT04328844		Active
PI3Kδ, PI3Kγ	Duvelisib	Lymphoma, leukemia				Marketed
PI3Kδ, PI3Kγ	Tenalisib (RP6530)	Breast cancer		Phase II — NCT05021900		Active
PI3Kα, PI3Kδ, PI3Kγ	Taselisib	Solid tumor, lymphoma, myeloma		Phase II — NCT02465060		Active
Undisclosed PI3K isoform inhibitor	TQ-B-3525	Lymphoma, leukemia, endometrial cancer, ovarian cancer, breast cancer		Phase II — NCT04615468, NCT04610970, NCT04398953, NCT04324879, NCT04836663, NCT04808570, NCT04355520		Active
	HMPL-689	Lymphoma		Phase II — NCT04849351		Active
PI3K, mTOR dual inhibitor	Paxalisib	CNS cancer		Phase III — NCT03970447		Active
	Samotolisib	Solid tumor, lymphoma		Phase II — NCT03213678, NCT03155620		Active
	Gedatolisib	Breast cancer		Phase II — NCT03698383, NCT03911973		Active
Various targets	Pictilisib (GDC-0941), Pilaralisib, ZSTK-474, Sonolisib, SAR260301, Seletalisib (UCB-5857), AMG319 (ACP-319), Nemiralisib (GSK2269557), Dezapelisib (NCB-040093), AZD-8835, Dactolisib, Apitolisib, SF1126, Bimiralisib (PQR309), Voxtalisib, etc					Inactive/discontinued
mTOR inhibitors
Allosteric mTOR inhibitor	Everolimus	Breast cancer, kidney cancer, endocrine tumor, CNS cancer				Marketed
	Sirolimus	Lymphangioleiomyomatosis (LAM)				Marketed
	Temsirolimus	Kidney cancer				Marketed
mTOR kinase inhibitor	Sapanisertib (MLN0128)	Solid tumor, lymphoma, myeloma		Phase II — NCT02465060		Active
	Vistusertib	Lung cancer		Phase II — NCT02664935, NCT03334617		Active
	CC-115	CNS cancer		Phase II — NCT02977780		Active
	Onatasertib (ATG-008)	Solid tumor		Phase II — NCT04518137, NCT03591965, NCT04998760, NCT04337463		Active
PI3K, mTOR dual inhibitor	Paxalisib	CNS cancer		Phase III — NCT03970447		Active
	Samotolisib	Solid tumor, lymphoma		Phase II — NCT03213678, NCT03155620		Active
	Gedatolisib	Breast cancer		Phase II — NCT03698383, NCT03911973		Active
Various targets	Dactolisib, Apitolisib, SF1126, Bimiralisib (PQR309), Voxtalisib, Ridaforolimus (Deforolimus, MK-8669), AZD8055					Inactive/discontinued
Akt inhibitors
Pan-Akt	Ipatasertib	Prostate cancer, breast cancer		Phase III — NCT04650581, NCT04177108, NCT04060862, NCT03337724, NCT03072238		Active
	Capivasertib	Breast cancer, prostate cancer		Phase III — NCT03997123, NCT04493853, NCT04862663, NCT04305496		Active
	Triciribine (PTX-200)	Leukemia		Phase II — NCT02930109		Active
	TAS-117	Solid tumor		Phase II — NCT04770246		Active
	Afuresertib	Ovarian cancer, prostate cancer		Phase II — NCT04060394, NCT04374630		Active
	MK-2206	Lung cancer, thymoma, breast cancer		Phase II — NCT01042379, NCT01306045		Active
	Uprosertib	Myeloma, solid tumor		Phase II — NCT01989598, NCT01902173		Active
Various targets	COTI-2, Perifosine, LY-2503029					Inactive/discontinued